Leighton Read was a managing director of Alloy Ventures, and is currently a Venture Partner at Brandon Capital, one of Australia’s life science venture capital firms. Previously, he founded Affymax NV, later sold to Glaxo SmithKline. He was the CEO of Aviron which developed FluMist™, the intranasal influenza vaccine acquired by MedImmune. Leighton has been a director of companies ranging from biotechnology, medical devices, materials science, energy and software. Leighton received a BS from Rice University, and an MD from the University of Texas Health Science Center at San Antonio.